BioTelemetry Stock Price, News & Analysis (NASDAQ:BEAT)

$42.06
+0.73 (+1.77 %)
(As of 09/22/2019 08:10 AM ET)
Today's Range
$41.1370
Now: $42.06
$42.20
50-Day Range
$38.8837
MA: $41.17
$44.48
52-Week Range
$38.45
Now: $42.06
$80.92
Volume196,764 shs
Average Volume261,827 shs
Market Capitalization$1.43 billion
P/E Ratio20.26
Dividend YieldN/A
Beta1.4
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. Read More…

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$399.47 million
Cash Flow$3.3487 per share
Book Value$9.32 per share

Profitability

Net Income$42.82 million

Miscellaneous

Employees1,500
Market Cap$1.43 billion
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.


BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) posted its earnings results on Tuesday, July, 30th. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.08. The medical research company had revenue of $111.80 million for the quarter, compared to analyst estimates of $111.11 million. BioTelemetry had a net margin of 11.06% and a return on equity of 22.98%. BioTelemetry's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $0.46 EPS. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BioTelemetry.

What price target have analysts set for BEAT?

5 analysts have issued 1-year target prices for BioTelemetry's stock. Their predictions range from $54.00 to $90.00. On average, they anticipate BioTelemetry's stock price to reach $77.60 in the next year. This suggests a possible upside of 84.5% from the stock's current price. View Analyst Price Targets for BioTelemetry.

What is the consensus analysts' recommendation for BioTelemetry?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry.

Has BioTelemetry been receiving favorable news coverage?

Media coverage about BEAT stock has been trending somewhat negative on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioTelemetry earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Some companies that are related to BioTelemetry include Acadia Healthcare (ACHC), Hanger (HNGR), IMAC (IMAC), AAC (AAC) and Biocorrx (BICX).

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Square (SQ), Alibaba Group (BABA), Netflix (NFLX), Adobe (ADBE), ABIOMED (ABMD), Veeva Systems (VEEV), Paypal (PYPL) and EXACT Sciences (EXAS).

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 44)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)
  • Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 55)

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.85%), BlackRock Inc. (14.85%), Vanguard Group Inc. (10.91%), Invesco Ltd. (3.76%), Stephens Investment Management Group LLC (1.98%) and Bank of New York Mellon Corp (1.84%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which institutional investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Wells Fargo & Company MN, Public Employees Retirement System of Ohio, AXA, Royal Bank of Canada, Navellier & Associates Inc, Russell Investments Group Ltd. and Ancora Advisors LLC. Company insiders that have sold BioTelemetry company stock in the last year include Fred Broadway, Heather C Getz, Kirk E Gorman, Peter Ferola and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Which institutional investors are buying BioTelemetry stock?

BEAT stock was bought by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Sio Capital Management LLC, Pembroke Management LTD, Morgan Stanley, JPMorgan Chase & Co. and Summit Creek Advisors LLC. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $42.06.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.43 billion and generates $399.47 million in revenue each year. The medical research company earns $42.82 million in net income (profit) each year or $1.94 on an earnings per share basis. BioTelemetry employs 1,500 workers across the globe.View Additional Information About BioTelemetry.

What is BioTelemetry's official website?

The official website for BioTelemetry is http://www.gobio.com/.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Featured Article: What is Forex?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel